이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

2026년 11월 12일 업데이트: Immorna Biotherapeutics, Inc.

Randomized, Double-Blinded, Placebo-Controlled Phase 1 Clinical Trial to Assess the Safety and Immunogenicity of Two Doses of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) in Healthy Participants

Herpes zoster is caused by reactivation of varicella zoster virus. This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of self-replicating RNA (srRNA) herpes zoster vaccine JCXH-105. Eligible participants will receive 2 doses of study vaccine/placebo at planned dose levels and follow scheduled safety and immunogenicity follow-up visits. The goal of this study is to assess the safety profile and immune response induced by JCXH-105.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

72

단계

  • 1단계

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

40년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • (1) Gender: Male or female; (2) Age: ≥ 40 years of age at screening. (3) Status: Healthy participants. (4) Subject agrees not to receive any other herpes zoster vaccine while participating in this study.

    (5) All Laboratory values required for screening prior to study enrollment are within normal limits or abnormal without clinical significance as judged by the investigator.

    (6) Female participants must meet the following criteria:

    • Surgically sterile or postmenopausal for ≥ 2 years, or women of childbearing potential (premenopausal or postmenopausal for < 2 years) who have a negative pregnancy test and are willing to use effective contraception from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.

    • Agree not to breastfeed from the first administration of investigational vaccine/placebo to at least 3 months after the full-course vaccination.

      (7) Male participants should meet the following criteria: agree to use effective contraception and not to donate sperms from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.

      (8) Able to fully understand and voluntarily sign the informed consent form.

Exclusion Criteria:

  • (1) Participants who have a history of herpes zoster or are currently diagnosed with herpes zoster, or have a history of chickenpox, or a history of close contact with chickenpox/herpes zoster patients within 30 days before enrollment.

    (2) History of chickenpox or herpes zoster vaccination. (3) Hypersensitivity to any component of the investigational vaccine/placebo, or any previous serious reaction to vaccination, or a history of serious allergic disease.

    (4) Fever within 3 days prior to enrollment, acute illness or acute exacerbation of chronic illness within 7 days prior to enrollment, or taking antipyretic, analgesic, and anti-allergic drugs within 3 days prior to enrollment.

    (5) History of significant cardiac disease, or myocarditis or pericarditis. (6) At present, participants with severe liver and kidney diseases, spleen dysfunction or asplenia, hypertension that cannot be controlled by drugs, diabetes with serious complications and other chronic diseases are currently suffering.

    (7) Use of whole blood, blood products, or immunoglobulins within 3 months prior to vaccination or planned use during the study.

    (8) Has received any inactive vaccine within 14 days prior to the first dose of vaccine.

    (9) Received the following within 28 days prior to the first dose of vaccine: Any live/mRNA vaccine; Immunomodulators or immunosuppressive drugs; Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor; Receiving systemic corticosteroids for 3 or more consecutive days. (Note: Study participants are permitted to receive long-term systemic prednisone at a dose ≤10 mg/day, or systemic corticosteroids equivalent to prednisone. Topical medications such as ointments, eye drops, inhalants or nasal sprays are allowed, provided that the topical medications should not exceed the recommended dose in the instructions and there are no signs of systemic exposure.) (10) Have confirmed or suspected immunosuppression, immunodeficiency, or autoimmune disease.

    (11) Positive screening test for HIV antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies.

    (12) Known history of active or latent tuberculosis (Mycobacterium tuberculosis).

    (13) Axillary temperature > 37.0 °C at enrollment. (14) Participation in another drug, device, or other vaccine clinical trial within 30 days prior to the first dose of investigational vaccine/placebo or planned participation during the study period.

    (15) Participants with dermatologic condition that could affect local solicited adverse reaction assessments (e.g., tattoos, psoriasis, patches affecting skin over the deltoid area).

    (16) Participants with contraindications to IM injection. (17) The investigator considers that there are other situations unsuitable for participating in this study, including but not limited to failure to participate in follow-up according to the study protocol.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Low-dose JCXH-105

Participants receive low dose of JCXH-105

Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

위약 비교기: Low-dose placebo

Participants receive low dose of placebo

Placebo (sodium chloride injection) as control

실험적: Medium-dose JCXH-105

Participants receive medium dose of JCXH-105

Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

위약 비교기: Medium-dose placebo

Participants receive medium dose of placebo

Placebo (sodium chloride injection) as control

실험적: High-dose JCXH-105

Participants receive high dose of JCXH-105

Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

위약 비교기: High-dose placebo

Participants receive high dose of placebo

Placebo (sodium chloride injection) as control

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Serious adverse events (SAEs)
기간: From Day 1 post- administration through 360 days after the full-course vaccination

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

From Day 1 post- administration through 360 days after the full-course vaccination
Solicited local injection site adverse events
기간: Within 14 days after each dose of investigational vaccine/placebo

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

Within 14 days after each dose of investigational vaccine/placebo
Solicited systemic adverse events
기간: Within 14 days after each dose of the investigational vaccine/placebo

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

Within 14 days after each dose of the investigational vaccine/placebo
Unsolicited AEs
기간: Within 30 days after each dose of the investigational vaccine/placebo

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

Within 30 days after each dose of the investigational vaccine/placebo
Laboratory parameters
기간: On the third day after each dose of the investigational vaccine/placebo

Clinically significant abnormal changes of laboratory parameters compared with pre-vaccination

On the third day after each dose of the investigational vaccine/placebo
Adverse events of special interest (AESIs)
기간: From Day 1 post administration through 360 days after the full-course vaccination

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

From Day 1 post administration through 360 days after the full-course vaccination

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2028년 3월 1일

연구 완료 (추정된)

2028년 3월 1일

연구 등록 날짜

최초 제출

2026년 11월 12일

QC 기준을 충족하는 최초 제출

2026년 11월 12일

처음 게시됨 (실제)

2026년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • JCXH-105-002

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .